tetano
Editor, Senior Moderator
Influenza Other Respir Viruses. 2014 Feb 18. doi: 10.1111/irv.12243. [Epub ahead of print]
HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children.
Leahy TR1, Goode M, Lynam P, Gavin PJ, Butler KM.
Author information
Abstract
DESIGN:
Children with HIV are especially susceptible to complications from influenza infection, and effective vaccines are central to reducing disease burden in this population. We undertook a prospective, observational study to investigate the safety and immunogenicity of the inactivated split-virion AS03-adjuvanted pandemic H1N1(2009) vaccine in children with HIV.
SETTING:
National referral centre for Paediatric HIV in Ireland.
SAMPLE:
Twenty four children with HIV were recruited consecutively and received two doses of the vaccine. The serological response was measured before each vaccine dose (Day 0 and Day 28) and 2 months after the booster dose. Antibody titres were measured using a haemagglutination inhibition (HAI) assay. Seroprotection was defined as a HAI titre ≥ 1:40; seroconversion was defined as a ≥ fourfold increase in antibody titre and a postvaccination titre ≥ 1:40.
MAIN OUTCOME MEASURES:
The seroconversion rates after prime and booster doses were 75% and 71%, respectively. HIV virological suppression at the time of immunization was associated with a significantly increased seroconversion rate (P = 0?009), magnitude of serological response (P = 0?02) and presence of seroprotective HAI titres (P = 0?017) two months after the booster dose. No other factor was significantly associated with the seroconversion/seroprotection rate. No serious adverse effects were reported. Vaccination had no impact on HIV disease progression. The AS03-adjuvanted pandemic H1N1 vaccine appears to be safe and immunogenic among HIV-infected children. A robust serological response appears to be optimized by adherence to a HAART regimen delivering virological suppression.
? 2014 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
KEYWORDS:
HIV , AS03 adjuvant, pandemic H1N1 influenza, vaccination
PMID:
24548473
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24548473
HIV virological suppression influences response to the AS03-adjuvanted monovalent pandemic influenza A H1N1 vaccine in HIV-infected children.
Leahy TR1, Goode M, Lynam P, Gavin PJ, Butler KM.
Author information
Abstract
DESIGN:
Children with HIV are especially susceptible to complications from influenza infection, and effective vaccines are central to reducing disease burden in this population. We undertook a prospective, observational study to investigate the safety and immunogenicity of the inactivated split-virion AS03-adjuvanted pandemic H1N1(2009) vaccine in children with HIV.
SETTING:
National referral centre for Paediatric HIV in Ireland.
SAMPLE:
Twenty four children with HIV were recruited consecutively and received two doses of the vaccine. The serological response was measured before each vaccine dose (Day 0 and Day 28) and 2 months after the booster dose. Antibody titres were measured using a haemagglutination inhibition (HAI) assay. Seroprotection was defined as a HAI titre ≥ 1:40; seroconversion was defined as a ≥ fourfold increase in antibody titre and a postvaccination titre ≥ 1:40.
MAIN OUTCOME MEASURES:
The seroconversion rates after prime and booster doses were 75% and 71%, respectively. HIV virological suppression at the time of immunization was associated with a significantly increased seroconversion rate (P = 0?009), magnitude of serological response (P = 0?02) and presence of seroprotective HAI titres (P = 0?017) two months after the booster dose. No other factor was significantly associated with the seroconversion/seroprotection rate. No serious adverse effects were reported. Vaccination had no impact on HIV disease progression. The AS03-adjuvanted pandemic H1N1 vaccine appears to be safe and immunogenic among HIV-infected children. A robust serological response appears to be optimized by adherence to a HAART regimen delivering virological suppression.
? 2014 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
KEYWORDS:
HIV , AS03 adjuvant, pandemic H1N1 influenza, vaccination
PMID:
24548473
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24548473